Abstract: An audio-visual live content delivery system includes a client having access to a provider network via a gateway, an audio-visual live content delivering equipment comprising a multicaster for transmitting audio-visual live contents in multicast form via the provider network, a de-multicaster being able to perform a conversion in unicast form of audio-visual live contents received in multicast form from the multicaster, and a controller managing routing of requests to get audio-visual live contents. The client performs a discovery procedure aiming at receiving information on potential presence and availability of the de-multicaster. When the client intends receiving a targeted audio-visual live content, the client sends to the controller a request providing indication of presence and availability, or not, of the de-multicaster. Then the controller decides how redirecting the client to fulfill the request, according at least to the indication of presence and availability, or not, of the de-multicaster.

Abstract: An optical fiber and an optical amplifier including the optical fiber are disclosed, the optical fiber includes a core region for guiding a propagation of a multimode optical signal, a cladding region laterally surrounding the core region and at least two doped rings, each of the at least two doped rings having a corresponding rare-earth or transition metal dopant concentration. The core region includes a central core having a first refractive index, at least one core layer laterally surrounding the central core, each of the at least one core layer having corresponding internal and external radii, an internal radius of an innermost core layer corresponding to a radius of the central core and an external radius of the outermost core layer corresponding to a radius of the core region.

Abstract: The disclosure provides gene therapy vectors and methods of use thereof for treating genetic diseases, such as lysosomal storage diseases. For example, the disclosure provides gene therapy vectors and methods for treating GM1 gangliosidosis. The disclosure also provide methods for making the provided gene therapy vectors.